Metaplastic rectal adenocarcinoma into metastatic mucinous carcinoma on the buttock: The efficacy of immunohistochemistry

Kiyohara, Takahiro; Nakamaru, Sei; Miyamoto, Mari; Shijimaya, Takako; Nagano, Naoko; Makimura, Kaoru; Tanimura, Hirotsugu

doi:10.1111/1346-8138.14873

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgical excision and carbon dioxide laser may remove disfiguring lesions and produced dramatic cosmetic improvement in short term, but recurrences were reported in 3 cases(2, 7, 9) (50%) out of 6, while another one case had difficulty in skin closure(4). One case reported no recurrence during oneyear follow-up(3), however, the other one didn't provide follow-up information (12). Systemic steroids had been tried without any response.…”

Section: Resultsmentioning

confidence: 99%

Effective treatment of progressive nodular histiocytosis by intermediate-dose cytarabine: a case report and literature review

Wang

Qiu

Sun

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Progressive nodular histiocytosis (PNH) is a rare, clinically distinct non-Langerhans cell histiocytosis, affecting the skin and mucous membranes with no signs of spontaneous regression of the lesions, without any other system involved. Patients typically have hundreds of lesions of superficial xanthomatous papules to nodules and deep larger fibrous nodules. So far, very few universally accepted reports of PNH existed and no effective treatment have been reported to reverse the progressive clinical course. Results Twenty-five PNH cases were identified so far, with a median age of 34 years. 14 patients were male. All patients presented as papules and nodules over the skin and/or mucosal surfaces, including face (39%), fingers or palm (16%), laryngeal (12%) and eyes (8%). 7 cases (28%) reported PNH with systematic diseases. Treatment efficacy using steroids, chemotherapy or surgical excision were disappointing in previous case reports. One patient with laryngeal involvement died due to airway obstruction. In our case, traditional chemotherapy achieved favorable therapeutic effect with intermediate-dose cytarabine confirmed by clinical symptoms of the patient, as well as PET/CT imaging. Conclusions PNH is a rare, proliferative disorder with disfiguring lesions and deteriorative quality of life. Intermediate-dose cytarabine should be considered as a treatment option for PNH patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Effective treatment of progressive nodular histiocytosis by intermediate-dose cytarabine: a case report and literature review

Wang

Qiu

Sun

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In addition, the lowly differentiated ones can hardly be cured, resulting in death rates of ~20%. In particular, EC cases with regional or distal metastasis tend to recur, and the effect of systemic therapies is limited (5)(6)(7)(8). Therefore, it is important to further explore the molecular mechanisms responsible for EC tumorigenesis and progression, and to develop novel diagnostic and therapeutic strategies.…”

Section: Introductionmentioning

confidence: 99%

Knockdown of SLCO4C1 inhibits cell proliferation and metastasis in endometrial cancer through inactivating the PI3K/Akt signaling pathway

Han

Bian

et al. 2020

Oncol Rep

View full text Add to dashboard Cite

Endometrial cancer (EC) is the second leading type of cancer among women, and its progression is dependent on several factors. The aim of the present study was to examine the effect of solute carrier organic anion transporter family member 4C1 (SLCO4C1) on human EC and determine the underlying molecular mechanism. A total of 57 differentially expressed genes associated with advanced stage and survival were identified in The Cancer Genome Atlas database. In addition, gene ontology analysis indicated that SLCO4C1 was highly expressed in cell differentiation and integral component of plasma membrane. High SLCO4C1 expression in EC tissues was verified by immunohistochemistry. The results demonstrated that the downregulation of SLCO4C1 could significantly suppress the viability, sphere formation, migration and invasion abilities of cells, but enhance apoptosis in EC cell lines. Furthermore, the present results demonstrated that SLCO4C1 had effects on the epithelial-mesenchymal transition (EMT) phenotype in EC cells and regulated the expression of EMT-related proteins. Mechanistically, the present study revealed that SLCO4C1 regulated the biological functions of EC cells by inactivating the PI3K/Akt signaling pathway. Collectively, it was demonstrated that the SLCO4C1/PI3K/Akt pathway may play an important role in EC progression and metastasis and serve as a potential biomarker and target for EC diagnosis and treatment.

show abstract

Metaplastic rectal adenocarcinoma into metastatic mucinous carcinoma on the buttock: The efficacy of immunohistochemistry

Cited by 2 publications

References 9 publications

Effective treatment of progressive nodular histiocytosis by intermediate-dose cytarabine: a case report and literature review

Effective treatment of progressive nodular histiocytosis by intermediate-dose cytarabine: a case report and literature review

Knockdown of SLCO4C1 inhibits cell proliferation and metastasis in endometrial cancer through inactivating the PI3K/Akt signaling pathway

Contact Info

Product

Resources

About